<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sixteen patients with intracerebral <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> received intraarterial <z:chebi fb="2" ids="27899">cisplatin</z:chebi>, teniposide, and BCNU combined with intravenous <z:chebi fb="2" ids="27899">cisplatin</z:chebi>, teniposide, and <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Oral <z:chebi fb="3" ids="17754">glycerol</z:chebi> and intravenous <z:chebi fb="1" ids="29864">mannitol</z:chebi> were given along with the intravenous chemotherapy in an attempt to increase drug delivery to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> by augmenting <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> blood flow </plain></SENT>
<SENT sid="2" pm="."><plain>Thirteen additional patients were treated with the same regimen, but received <z:hpo ids='HP_0000001'>all</z:hpo> the chemotherapy intravenously </plain></SENT>
<SENT sid="3" pm="."><plain>Of the 16 patients receiving intraarterial chemotherapy (median survival, 14 weeks), none responded, 5 (31%) were stable for &gt; 8 weeks, 8 (50%) failed, and 3 (19%) were unevaluable due to early <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Of the 13 patients receiving <z:hpo ids='HP_0000001'>all</z:hpo> their treatment intravenously (median survival, 13 weeks), 3 (23%) responded, 1 (8%) was stable, 7 (54%) failed, and 2 (15%) were unevaluable due to early <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In the patients receiving intraarterial chemotherapy, toxicity included ipsilateral <z:chebi fb="46" ids="15035">retinal</z:chebi> toxicity (2 patients), <z:hpo ids='HP_0200026'>ocular pain</z:hpo> or <z:hpo ids='HP_0002315'>headache</z:hpo> (10), periorbital swelling and flushing (6), increased <z:hpo ids='HP_0002181'>brain edema</z:hpo> with focal neurological deficits and <z:hpo ids='HP_0002329'>drowsiness</z:hpo> (5), and catheter-related carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> followed by fatal <z:e sem="disease" ids="C0019270" disease_type="Disease or Syndrome" abbrv="">herniation</z:e> (1) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">Myelosuppression</z:e> was worse in patients who received <z:hpo ids='HP_0000001'>all</z:hpo> their treatment intravenously than in those receiving intraarterial chemotherapy (p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Neutropenic <z:hpo ids='HP_0100806'>sepsis</z:hpo> developed in 4 patients on the intraarterial arm (1 fatal) and in 5 patients on the intravenous arm (2 fatal) </plain></SENT>
<SENT sid="8" pm="."><plain>Other toxic effects were similar whether or not patients received intraarterial treatment or only intravenous treatment </plain></SENT>
<SENT sid="9" pm="."><plain>Overall, toxicity of this regimen was excessive, and response rates were lower than would have been expected with single agent therapy </plain></SENT>
</text></document>